#ESMO25: Innovative strategies produced mixed results in #RareCancers, but encouraging efficacy was demonstrated with #immunotherapy in Merkel-cell carcinoma and with belzutifan in phaeochromocytoma and paragangliomas.
More in the #ESMODailyReporter 📌 https://ow.ly/7GP350XjGXX

#ESMO25: Adjuvant ALK tyrosine kinase inhibitors (#TKIs) show robust and durable disease-free survival benefit in phase III ELEVATE and ALINA #ClinicalTrials of ALK+ #NSCLC.
Read more in the #ESMODailyReporter 📌https://ow.ly/mvek50XjBS5
@marcello_tiseo
#LungCancer #TargetedTherapy

#ESMO25: First evidence for the efficacy and safety of #TargetedTherapy in #mesothelioma reported as two novel TEAD inhibitors show clinical activity and manageable toxicity in heavily pre-treated patients.
📌Read more in the #ESMODailyReporter https://ow.ly/FARM50XkmWE

#ESMO25: Adding #immunotherapy to radiotherapy improved rates of pathological response in resectable #sarcoma, but #biomarkers and histology-focused trials are needed to further improve outcomes.
Read more #ESMODailyReporter 📌 https://ow.ly/UVkF50XifKb

#ESMO25: In #thymic epithelial tumours, rivoceranib after prior therapy and peri-operative pembrolizumab demonstrated promising efficacy but were not superior to standard therapies. Read more in the #ESMODailyReporter 📌 https://ow.ly/22ES50XiaXb

#RareCancers

#ESMO25: Studies investigated different approaches to restore sensitivity in anti-PD-(L)1 relapsed/refractory solid tumours: GDF-15 inhibition, mRNA-based therapy and targeting VISTA. Read more in the #ESMODailyReporter 📌 https://ow.ly/H8S950XeQQj

#ImmunoOncology

Karim Fizazi in #ESMODailyReporter: the tissue-agnostic approach to #CancerTreatment holds promise but is still challenged by #ClinicalTrial design and regulatory processes.
#ESMO25
📌https://ow.ly/PkGG50Xfmbr

#ESMO25: Regular exercise has a significant impact on patient survival, but how can physical activity be integrated into the patient journey? Pr Michel Ducreux considers barriers and possible solutions.
#ESMODailyReporter📌 https://ow.ly/zect50Xezeq

#CancerCare #CancerManagement

#ESMO25: Positive phase III #ClinicalTrial data with T-DXd in high-risk, HER2+ #EarlyBreastCancer suggest that a paradigm change in the treatment of these patients may be imminent.
Read more in the #ESMODailyReporter 📌 https://ow.ly/n1y050Xeuz0

#BreastCancer #ADC